Xlumena said it closed a $25 million Series C round it plans to use to expand its commercial footprint and win FDA clearance for its Axios stent and delivery system.
Xlumena wraps up $25M Series C round
Charter Life Sciences
Mirabilis Medica pulls in $13M Series A round for ultrasound fibroid device
Mirabilis Medica said it raised up to $13 million in a Series A1 round and tapped a new CEO to lead the development of its ultrasound treatment for uterine fibroids.
The Bothell, Wash.-based medical device company said it closed on an initial $7 million round led by GSR Ventures, including $4 million in cash and a $3 million conversion of debt to equity. Charter Life Sciences also participated in the round.
